Qatar Diabetes Mobile Application Trial (QDMAT): an open-label randomised controlled trial to examine the impact of using a mobile application to improve diabetes care in type 2 diabetes mellitus-a study protocol

Noor Suleiman, Meis Alkasem, Zaina Al Amer, Obada Salameh, Noora Al-Thani, Mohammad Khair Hamad, Khaled Baagar, Ibrahem Abdalhakam, Manal Othman, Ragae Dughmosh, Dabia Al-Mohanadi, Ali Al Sanousi, Mohammed Bashir, Odette Chagoury, Shahrad Taheri, Abdul-Badi Abou-Samra, Noor Suleiman, Meis Alkasem, Zaina Al Amer, Obada Salameh, Noora Al-Thani, Mohammad Khair Hamad, Khaled Baagar, Ibrahem Abdalhakam, Manal Othman, Ragae Dughmosh, Dabia Al-Mohanadi, Ali Al Sanousi, Mohammed Bashir, Odette Chagoury, Shahrad Taheri, Abdul-Badi Abou-Samra

Abstract

Background: Mobile health (mHealth) is increasingly advocated for diabetes management. It is unclear if mobile applications are effective in improving glycaemic control, clinical outcomes, quality of life and overall patient satisfaction in patients with type 2 diabetes (T2DM). A new mobile application was specifically built for people with T2DM with the help of the local expertise. The objective of the study was to evaluate the effectiveness of the mobile app.

Methods: The planned study is an ongoing open-label randomised controlled trial in which adults living with T2DM treated with insulin will be randomised 1:1 to the use of this diabetes application versus current standard care. The primary outcome will be the difference in mean HbA1c from baseline to 6 months. Other outcome measures include anthropometric measures, hypoglycaemic events, medication adjustments, number of clinical interactions and missed appointments and patient perceptions of their disease and diabetes self-management. The study will randomise 180 subjects for assessment of the primary outcome.

Discussion: We hypothesise that the diabetes-specific mobile application will improve glycaemic control, increase patient empowerment for self-management of diabetes and improve interaction between patients and healthcare providers. If the Qatar Diabetes Mobile Application Trial (QDMAT) demonstrates this, it will inform clinical services for the future self-management of T2DM.

Trial registration: ClinicalTrials.gov Identifier: NCT03998267 . Registered on 26 June 2019.

Keywords: Clinical trial; Lifestyle change; Mobile health; Self-management; Type 2 diabetes mellitus.

Conflict of interest statement

The authors declare that they have no competing interests. ST has been on the clinical advisory group for Novo Nordisk (Denmark). The investigators have contributed to the refinement of the Droobi app.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
The Droobi app. a Home/landing page. b Blood glucose level entry. c Body weight entry. d Food portions entry. e Food photo entry. f Activity entry. g Toolbox educational curriculum. h Lesson 1 from the curriculum
Fig. 2
Fig. 2
The Droobi app healthcare provider portal. a Portal landing page-dashboard. b Chat function amongst healthcare team. c Report created by Droobi upon request of educator for physician approval: (i) expanded report view showing glucose monitoring chart and ability to review previous blood glucose readings in chart and table format; (ii) expanded report view showing medication and blood glucose monitoring plan together with diet goals, notes for the team and the assigned healthcare team
Fig. 3
Fig. 3
Flow of participants

References

    1. Ansari-Moghaddam A, Setoodehzadeh F, Khammarnia M, Adineh HA. Economic cost of diabetes in the Eastern Mediterranean region countries: A meta-analysis. Diabetes Metab Syndr. 2020;14(5):1101–1108. doi: 10.1016/j.dsx.2020.06.044.
    1. IDF Diabetes Atlas. . Accessed 23 May 2021.
    1. Zaghloul H, Elshakh H, Elzafarany A, Chagoury O, McGowan B, Taheri S. A systematic review of randomized controlled trials of dietary interventions for weight loss in adults in the Middle East and north Africa region. Clin Obes. 2020:e12434.
    1. Zawiejska A, McAleese J, Yemparala P, Taheri S. Treatment intensification in type 2 diabetes mellitus and obesity. Br J Gen Pract. 2013;63(609):182. doi: 10.3399/bjgp13X665152.
    1. Choudhury S, Hussain S, Yao G, Hill J, Malik W, Taheri S. The impact of a diabetes local enhanced service on quality outcome framework diabetes outcomes. PLoS One. 2013;8(12):e83738. doi: 10.1371/journal.pone.0083738.
    1. Diabetes in adults. . Accessed 23 May 2021.
    1. Brown A, Guess N, Dornhorst A, Taheri S, Frost G. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: what can be done? Diabetes Obes Metab. 2017;19(12):1655–1668. doi: 10.1111/dom.13009.
    1. Hood M, Wilson R, Corsica J, Bradley L, Chirinos D, Vivo A. What do we know about mobile applications for diabetes self-management? A review of reviews. J Behav Med. 2016;39(6):981–994. doi: 10.1007/s10865-016-9765-3.
    1. Kvedar JC, Fogel AL. mHealth advances clinical research, bit by bit. Nat Biotechnol. 2017;35(4):337–339. doi: 10.1038/nbt.3851.
    1. mHealth: new horizons for health through mobile technologies: second global survey on eHealth. World Health Organization. . Accessed 23 May 2021.
    1. Obro LF, Heiselberg K, Krogh PG, Handberg C, Ammentorp J, Pihl GT, et al. Combining mHealth and health-coaching for improving self-management in chronic care. A scoping review. Patient Educ Couns. 2021;104(4):680–8. doi: 10.1016/j.pec.2020.10.026.
    1. Cui M, Wu X, Mao J, Wang X, Nie M. T2DM self-management via smartphone applications: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166718. doi: 10.1371/journal.pone.0166718.
    1. Kitsiou S, Pare G, Jaana M, Gerber B. Effectiveness of mHealth interventions for patients with diabetes: an overview of systematic reviews. PLoS One. 2017;12(3):e0173160. doi: 10.1371/journal.pone.0173160.
    1. Rhee SY, Kim C, Shin DW, Steinhubl SR. Present and future of digital health in diabetes and metabolic disease. Diabetes Metab J. 2020;44(6):819–827. doi: 10.4093/dmj.2020.0088.
    1. Doyle-Delgado K, Chamberlain JJ. Use of diabetes-related applications and digital health tools by people with diabetes and their health care providers. Clin Diabetes. 2020;38(5):449–461. doi: 10.2337/cd20-0046.
    1. Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH, El Khatib N, Amona RA, El Nahas K, Suleiman N, Alnaama A, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(6):477–489. doi: 10.1016/S2213-8587(20)30117-0.
    1. Zaghloul H, Chagoury O, Elhadad S, Hayder Ahmed S, Suleiman N, Al Naama A, El Nahas K, Al Hamaq A, Charlson M, Wells MT, et al. Clinical and metabolic characteristics of the Diabetes Intervention Accentuating Diet and Enhancing Metabolism (DIADEM-I) randomised clinical trial cohort. BMJ Open. 2020;10(12):e041386. doi: 10.1136/bmjopen-2020-041386.
    1. Choudhury SM, Arora T, Alebbi S, Ahmed L, Aden A, Omar O, Taheri S. How do Qataris source health information? PLoS One. 2016;11(11):e0166250. doi: 10.1371/journal.pone.0166250.
    1. Alotaibi MM, Istepanian R, Philip N. A mobile diabetes management and educational system for type-2 diabetics in Saudi Arabia (SAED) Mhealth. 2016;2:33. doi: 10.21037/mhealth.2016.08.01.
    1. Abdalrazaq A, Suleiman N, Baagar K, Jandali N, Alhuwail D, Abdalhakam I, Shahbal S, Abou-Samra AB, Househ M. Patients and healthcare workers experience with a mobile application for self-management of diabetes in Qatar: a qualitative study. Comput Methods Prog Biomed Update. 2021;16(8):1–7.
    1. Tohid H, Choudhury SM, Agouba S, Aden A, Ahmed LHM, Omar O, Chagoury O, Taheri S. Perceptions and attitudes to clinical research participation in Qatar. Contemp Clin Trials Commun. 2017;8:241–247. doi: 10.1016/j.conctc.2017.10.010.
    1. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diab Care. 2021;44(Supplement_1):S15–33. 10.2337/dc21-S002.
    1. Qatar National Guideline: diabetes mellitus in type 2 in adults & elderly. . Accessed 23 May 2021.
    1. Schmitt A, Gahr A, Hermanns N, Kulzer B, Huber J, Haak T. The Diabetes Self-Management Questionnaire (DSMQ): development and evaluation of an instrument to assess diabetes self-care activities associated with glycaemic control. Health Qual Life Outcomes. 2013;11:138. doi: 10.1186/1477-7525-11-138.
    1. Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, Jackson RA. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28(3):626–631. doi: 10.2337/diacare.28.3.626.
    1. Taheri S, Chagoury O, Zaghloul H, Elhadad S, Ahmed SH, Omar O, Payra S, Ahmed S, El Khatib N, Amona RA, et al. Diabetes Intervention Accentuating Diet and Enhancing Metabolism (DIADEM-I): a randomised controlled trial to examine the impact of an intensive lifestyle intervention consisting of a low-energy diet and physical activity on body weight and metabolism in early type 2 diabetes mellitus: study protocol for a randomized controlled trial. Trials. 2018;19(1):284. doi: 10.1186/s13063-018-2660-1.
    1. Taheri S, Chagoury O, Tourette M, Skaroni I, Othman M, Bashir M, Dukhan K, Al Mohannadi D, Hassan D, Ghadban W, et al. Managing diabetes in Qatar during the COVID-19 pandemic. Lancet Diabetes Endocrinol. 2020;8(6):473–474. doi: 10.1016/S2213-8587(20)30154-6.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться